ArticleScientific reports2021
Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Metabolomic characteristics and related pathways in patients with different severity of COVID-19: a systematic review and meta-analysis.Journal of global health · 2025Pooled it
- Combining label-free Raman spectroscopy with machine learning to monitor COVID-19 disease from acute infection to recovery.Journal of biomedical optics · 2026Article
- A quantitative metabolic signature of host response during SARS-CoV-2 infection and recovery.iScience · 2026Article
- Association of a five-metabolite and early-symptom profile with Parkinson's disease and its clinical progression.Scientific reports · 2026Article
- Dynamic serum metabolomic changes during Chinese herbal hot compress therapy for postpartum uterine involution: pathway analysis and candidate biomarker identification.Frontiers in medicine · 2026Article
- Article
- SMART 2.0 Statistical Metabolomics Analysis: An R Tool 2.0.Analytical chemistry · 2025Article
- Temporal Changes in Blood Metabolome Among Patients on Hemodialysis.Kidney international reports · 2025Article
- Multi-omics analysis of two rat models reveals potential role of vesicle transport and autophagy in right ventricular remodeling.Scientific reports · 2025Article
- Metabolomic profile of severe COVID-19 and a signature predictive of progression towards severe disease status: a prospective cohort study (METCOVID).Scientific reports · 2025Article
- Comprehensive, Quantitative Analysis of SRM 1950: the NIST Human Plasma Reference Material.Analytical chemistry · 2025Article
- Comprehensive clinical and metabolomics profiling of COVID-19 Mexican patients across three epidemiological waves.Frontiers in molecular biosciences · 2025Article
- Multi-Omics Research on Angina Pectoris: A Novel Perspective.Aging and disease · 2024Review
- Metabolomic Insights into COVID-19 Severity: A Scoping Review.Metabolites · 2024Article
- Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts.Scientific reports · 2024Article
- Metabolic profiling reveals circulating biomarkers associated with incident and prevalent Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Postmortem metabolomics as a high-throughput cause-of-death screening tool for human death investigations.iScience · 2024Article
- Using a targeted metabolomics approach to explore differences in ARDS associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia.Critical care (London, England) · 2024Article
- Unraveling lipid and inflammation interplay in cancer, aging and infection for novel theranostic approaches.Frontiers in immunology · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
Abstract
Research exploring the development and outcome of COVID-19 infections has led to the need to find better diagnostic and prognostic biomarkers. This cross-sectional study used targeted metabolomics to identify potential COVID-19 biomarkers that predicted the course of the illness by assessing 110 endogenous plasma metabolites from individuals admitted to a local hospital for diagnosis/treatment. Patients were classified into four groups (≈ 40 each) according to standard polymerase chain reaction (PCR) COVID-19 testing and disease course: PCR-/controls (i.e., non-COVID controls), PCR+/not-hospitalized, PCR+/hospitalized, and PCR+/intubated. Blood samples were collected within 2 days of admission/PCR testing. Metabolite concentration data, demographic data and clinical data were used to propose biomarkers and develop optimal regression models for the diagnosis and prognosis of COVID-19. The area under the receiver operating characteristic curve (AUC; 95% CI) was used to assess each models' predictive value. A panel that included the kynurenine: tryptophan ratio, lysoPC a C26:0, and pyruvic acid discriminated non-COVID controls from PCR+/not-hospitalized (AUC = 0.947; 95% CI 0.931-0.962). A second panel consisting of C10:2, butyric acid, and pyruvic acid distinguished PCR+/not-hospitalized from PCR+/hospitalized and PCR+/intubated (AUC = 0.975; 95% CI 0.968-0.983). Only lysoPC a C28:0 differentiated PCR+/hospitalized from PCR+/intubated patients (AUC = 0.770; 95% CI 0.736-0.803). If additional studies with targeted metabolomics confirm the diagnostic value of these plasma biomarkers, such panels could eventually be of clinical use in medical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.